Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Malignant cardiac tumors

Primary malignant cardiac tumors are neoplasms arising from the tissues of the heart or pericardium with infiltrative and destructive potential and, depending on the histological type, metastatic potential. They encompass biologically distinct diseases: sarcomas arise from mesenchymal tissues, lymphomas from the proliferation of lymphoid cells, and mesotheliomas from the pericardial serosal lining. A cardiac location adds a particular functional vulnerability to oncological malignancy: even relatively limited growth may impair a valve, a coronary artery, or the conduction system, while a large mass may remain minimally symptomatic until hemodynamic compensation fails.

These are very rare diseases. The percentages reported in autopsy series, pathology archives, and cardiac surgery centers describe selected populations and cannot be equated with population incidence. Among primary adult cardiac neoplasms, benign forms predominate overall; among malignant forms, sarcomas constitute the main group. Cardiac involvement by an extracardiac tumor is more common overall: cardiac metastases must therefore first be distinguished from primary neoplasms, even when a cardiac manifestation leads to the initial diagnosis.

The expression “malignant tumor of the heart” therefore identifies a clinical problem, but becomes therapeutically meaningful only when the histological type, extent, and cardiovascular consequences have been defined. A potentially resectable localized sarcoma, a lymphoma responsive to systemic therapy, and a diffuse pericardial neoplasm require different strategies. The diagnostic pathway must establish this distinction promptly while preserving the patient's stability and the ability to obtain an adequate specimen.

Classification, origin, and predisposing factors

Cardiac sarcoma encompasses tumors showing vascular, muscular, osteogenic, or poorly defined differentiation. Cardiac angiosarcoma shows endothelial differentiation and preferentially involves the right atrium. Undifferentiated forms and many intimal sarcomas more frequently affect the left heart. Cardiac leiomyosarcoma shows smooth-muscle differentiation; other, very rare variants produce osteoid matrix or harbor specific molecular alterations. These anatomic associations guide clinical suspicion, whereas definitive classification requires integration of tissue findings.

The classification of sarcomas has been revised with the introduction of molecular testing. In particular, MDM2 amplification, interpreted within the appropriate morphological context, has made it possible to identify a subset of intimal sarcomas previously classified as undifferentiated tumors. Immunohistochemical positivity for a protein and amplification of its corresponding gene are distinct observations. The reported frequencies of individual histological types therefore also depend on the diagnostic criteria adopted and the period in which cases were collected.

Primary cardiac lymphoma is a lymphoid neoplasm originating in or predominantly involving the heart and pericardium; its operational definition may vary between studies. Most cases are aggressive B-cell lymphomas, particularly diffuse large B-cell lymphoma. It can occur in immunocompetent individuals or in the setting of immunosuppression. Identifying the cell lineage, immunophenotypic profile, and any extracardiac disease is essential for distinguishing a primary presentation from cardiac involvement by systemic lymphoma.

Pericardial mesothelioma arises from mesothelial cells and tends to spread along the serosa, producing nodules, thickening, and effusion. Its biology and the difficulty of resection differ from those of a circumscribed intracavitary mass. Assigning a neoplasm to the pericardium requires exclusion of a pleural origin or another contiguous disease. Here too, familiarity with tumors at other sites does not justify automatically transferring the frequencies of risk factors, prognostic criteria, or treatment outcomes to the rare pericardial location.

For most malignant cardiac tumors, no identifiable individual cause is found. Hereditary predisposition concerns selected subgroups and should be considered in light of age, personal history, family clustering, and histological type. Previous thoracic radiotherapy and immunosuppression are relevant history elements, with different significance depending on the suspected neoplasm. The presence of a cardiac mass in a patient with cancer also requires concurrent assessment of metastasis, thrombosis, treatment effects, and a possible second primary tumor.

Pathogenesis and pathophysiological consequences

Neoplastic transformation alters the proliferation, differentiation, and invasive capacity of the cells of origin. In sarcomas, genomic instability and abnormalities in cellular control pathways may be associated with disorganized growth, necrosis, and neovascularization. In lymphomas, lymphoid infiltration predominates and may spread through the walls, atrioventricular grooves, and pericardium. Mesothelioma may progressively envelop the heart. The anatomical behavior thus translates tumor biology into different patterns of injury, from replacement of myocardium to occupation of a chamber or stiffening of the serosa.

An intracavitary mass may cause obstruction of filling or ejection and interfere with valve leaflet coaptation. In the left heart, upstream pressures increase, with pulmonary congestion and reduced cardiac output; in the right heart, systemic venous hypertension and obstruction of caval return predominate. Myocardial infiltration reduces contractile function and compliance even without a predominant intracavitary mass. Thus, a preserved ejection fraction can coexist with substantial impairment of filling or critical obstruction.

Involvement of the conduction system may cause atrioventricular blocks, while the heterogeneity of infiltrated tissue favors atrial or ventricular arrhythmias. Extension to the coronary arteries may cause compression, encasement, or vascular invasion, with ischemia. Irregular endocardial surfaces facilitate thrombus deposition and detachment of neoplastic material. Emboli arising from the left heart reach the systemic circulation; those originating in the right heart usually enter the pulmonary circulation. Hematogenous metastasis, in turn, depends on the tumor's biology and routes of spread.

Pericardial invasion impairs fluid drainage and may promote a hemorrhagic effusion, particularly suggestive of certain vascular tumors. Tamponade depends on the rate of accumulation and the pericardial pressure–volume relationship, as well as the amount of fluid. Diffuse growth may also cause constriction or effusive-constrictive physiology. Fever, anemia, cachexia, and coagulation activation add systemic injury, exacerbating dyspnea, fatigue, and thrombotic risk.

Clinical manifestations, history, and physical examination

The most common presentation is a variable combination of dyspnea, reduced exercise capacity, chest pain, palpitations, and constitutional symptoms. The speed of progression matters: newly developed heart failure progressing over weeks, an effusion recurring after drainage, or a conduction block associated with a mass calls for an integrated interpretation. Fever, night sweats, and weight loss may suggest neoplastic or lymphoproliferative disease, although they overlap with infections and inflammatory disorders.

The medical history establishes the sequence of symptoms, previous tumors, cancer therapies, radiation exposure, immunosuppression, infections, and thrombotic risk factors. A history of atrial fibrillation, cardiomyopathy, or an intravascular device changes the assessment relative to thrombus. A family history of early-onset neoplasms and the presence of multiple tumors in the same individual may warrant genetic counseling. Previous imaging studies are particularly valuable because they can document onset, growth, and changes in location or infiltration.

The physical examination looks for tachycardia, hypotension, hypoxemia, jugular venous distension, edema, hepatomegaly, ascites, and signs of pulmonary congestion. New murmurs may result from obstruction or regurgitation, while muffled heart sounds and pulsus paradoxus may accompany a hemodynamically significant effusion. Assessment also encompasses lymph nodes, skin, signs of thromboembolism, and neurological findings. No single sign identifies the histological type: its value lies in recognizing the dominant mechanism and the urgency of care.

Syncope may reflect low cardiac output, arrhythmia, or impaired flow; a neurological deficit may result from embolism, metastasis, or hemorrhage. Shock, tamponade, acute pulmonary edema, unstable arrhythmia, and severe obstruction require immediate treatment. Under these circumstances, the oncological workup is coordinated with stabilization, obtaining diagnostic material during necessary procedures whenever feasible and safe.

Initial investigations and differential diagnosis

Transthoracic echocardiography is usually the first examination: it identifies location, size, mobility, attachment base, relationships to valves, and effusion, integrating these findings with gradients, ventricular function, and estimated pressures. Transesophageal echocardiography provides further assessment of posterior structures, septa, valves, and venous connections in relevant cases. Mass visibility depends on the acoustic window and location; a limited examination or an apparent absence of an intracavitary mass does not rule out mural or pericardial infiltration.

Cardiac magnetic resonance imaging defines extension within the walls, the relationship with viable myocardium, and tissue characteristics through morphological, cine, T1- and T2-weighted, perfusion, and late-enhancement sequences. Heterogeneity, necrosis, infiltration, and vascularity may support suspicion of malignancy. These findings acquire meaning in combination: some benign lesions are also vascularized, and a thrombotic component may conceal neoplastic tissue. MRI characterizes the process and helps plan sampling without replacing histopathological diagnosis when needed.

Contrast-enhanced CT provides a detailed depiction of coronary arteries, great vessels, calcifications, and thoracic structures; it is useful when MRI is not feasible and for extracardiac staging. Fluorodeoxyglucose PET may help identify metabolically active tissue, other disease sites, and an accessible biopsy target. Physiological myocardial uptake requires appropriate preparation, and inflammatory activity may produce findings overlapping with tumors. The indication for PET depends on the clinical question and suspected histological type.

The electrocardiogram, complete blood count, renal and liver function tests, electrolytes, inflammatory markers and, depending on the presentation, troponin and natriuretic peptides describe injury and functional reserve. Cardiac biomarkers indicate stress or injury but do not identify a specific neoplasm. When infection is suspected, blood cultures and microbiological investigations are added; in possible lymphoproliferative disease, markers of activity and metabolic risk are also evaluated and interpreted with the hematologist.

The differential diagnosis includes thrombi, vegetations, benign tumors, pseudomasses, and secondary deposits. A location atypical for myxoma, a broad attachment, invasion of multiple structures, rapid growth, and recurrent effusion increase oncological suspicion. An organized thrombus may have complex imaging features, and a tumor may have an adherent thrombus: a partial response to anticoagulation does not necessarily establish that a lesion is exclusively thrombotic. Interpretation requires agreement between history, anatomy, perfusion, and changes over time.

Histological diagnosis and selection of the sampling site

Tissue confirmation is central when diagnosis determines systemic treatment or when radiological appearances leave alternatives requiring divergent therapies. Selecting the sampling site requires consideration of diagnostic yield, bleeding risk, embolization, and possible interference with future resection. An accessible lymph node or metastasis may offer a safer route than cardiac sampling, provided the finding belongs to the same disease. In immediately operable tumors requiring removal for hemodynamic reasons, the surgical specimen may be the main diagnostic sample.

Intracardiac biopsy requires imaging guidance and an experienced team. Viable areas must be identified, avoiding necrosis, isolated thrombus, and sites at high risk of perforation whenever possible. A hypervascular or friable mass calls for particular caution. When lymphoma is likely, sampling should be coordinated with the laboratory to preserve material suitable for immunophenotyping and complementary tests. An insufficient tissue sample can delay the very treatment that biopsy is intended to expedite.

Examination of pericardial fluid can contribute to diagnosis through cytology, cell-block preparation, and, when appropriate, flow cytometry. A negative result does not eliminate suspicion when imaging and the clinical course suggest neoplasia, because a tumor may shed few cells into the effusion. Histology integrates architecture, atypia, mitoses, and necrosis with immunohistochemical panels and targeted molecular studies. Review by a pathologist experienced in sarcomas or hematopathology reduces the risk of assigning treatment on the basis of incomplete classification.

Staging, resectability, and cardiovascular reserve

After diagnosis has been established, local extent and dissemination are described separately. Local staging defines myocardial invasion, septal and valve involvement, coronary involvement, extension to great vessels, and pericardial spread. The absence of metastases does not automatically imply resectability: a neoplasm confined to the heart may involve structures whose removal would prevent adequate circulatory function. Conversely, a large mass may be resectable with reconstruction if its anatomical planes and location permit it.

For sarcomas, chest CT particularly looks for pulmonary metastases; imaging of the abdomen, pelvis, brain, or other regions is adapted to the histological type and symptoms. In angiosarcoma, brain imaging deserves specific consideration. In lymphomas, PET/CT and additional hematological investigations follow criteria specific to lymphoproliferative disease. Distinguishing an indeterminate nodule from a documented metastasis or an inflammatory finding is important when it changes the treatment goal.

Assessment of cardiac reserve covers right and left heart function, valves, conduction, coronary arteries, and the effects of effusion. Functional status, nutrition, renal and hepatic function, bleeding risk, and prior treatments are also assessed. These data inform both surgical planning and selection of potentially cardiotoxic drugs. Decisions are developed jointly by cardiology, cardiac surgery, oncology or hematology, radiology, pathology, and radiotherapy specialists experienced with rare tumors.

Treatment and integration of therapies

Emergencies require intervention on the hemodynamic mechanism: drainage of tamponade, control of an unstable arrhythmia, treatment of congestion, or surgery for critical obstruction. Diuretics and vasodilators must be tailored to the patient's physiology because marked preload dependence may make indiscriminate reduction of filling dangerous. Anticoagulation, if considered, must address a specific thrombotic indication and be balanced against tumor bleeding, hemorrhagic effusion, and planned procedures.

In localized sarcomas, the surgical objective is complete resection with microscopically negative margins when compatible with functional reconstruction. Removing only the portion protruding into a cavity may leave disease in the wall. Preoperative chemotherapy, postoperative treatment, and radiotherapy are discussed according to histological type, risk of progression, margins, and tolerability. Cardiac-specific evidence comes primarily from retrospective series; the benefit of a multimodal strategy does not prove that every component is required for every patient.

In lymphoma, systemic treatment is the cornerstone and can produce rapid shrinkage of the mass. In CD20-positive B-cell lymphomas, combinations containing rituximab and cytotoxic drugs are used, selected according to hematological classification and cardiac function. Surgery retains selected indications, mainly diagnostic or related to mechanical compromise. Initiating treatment for an extensively infiltrating lesion may require intensive monitoring for arrhythmias, hemodynamic changes, and tumor lysis syndrome.

For pericardial mesothelioma, spread along the serosa often makes radical resection difficult. Procedures to control effusion or constriction, surgery in selected cases, and oncological treatments are considered in light of evidence available for mesotheliomas, explicitly acknowledging the limits of extrapolation. Radiotherapy for cardiac neoplasms requires planning that accounts for motion and dose to healthy structures; its goal may be local control or palliation, depending on location and histological type.

Cardio-oncology accompanies the entire pathway. Anthracyclines, targeted agents, and irradiation may add toxicity to a heart already compromised by the tumor. Baseline assessment, monitoring of cardiac function and biomarkers when indicated, treatment of risk factors, and prompt management of dysfunction support continuity of therapy. Supportive care includes relief of pain and dyspnea, nutrition, adapted rehabilitation, and psychological support; early integration is appropriate even during treatment with curative intent.

Prognosis and surveillance

Prognosis is heterogeneous and depends mainly on histological type, extent, possibilities for local control, systemic response, and cardiovascular compromise. In sarcomas, dissemination and residual tumor are major problems; in lymphomas, complete response may profoundly alter the course, even after a severe clinical presentation. Statistics derived from small surgical cohorts or historical registries must be interpreted in light of patient selection, classifications used, and treatments available during the period studied.

Follow-up combines detection of recurrence with evaluation of cardiac injury. Echocardiography and MRI assess the treated site, function, and possible residual disease; CT and other investigations follow the histological type's risk of spread. In lymphomas, metabolic response is interpreted using dedicated hematological criteria. Intervals and duration are individualized, with closer surveillance during high-risk phases. New dyspnea, syncope, palpitations, neurological signs, or recurrence of effusion prompt reassessment ahead of the scheduled visit.

Complications of the disease and its treatments

Direct complications include heart failure, valve or vascular obstruction, valvular regurgitation, arrhythmias, conduction blocks, coronary ischemia, embolization, and tamponade. In some vascular neoplasms, hemorrhage and rupture of infiltrated structures may occur. Extracardiac progression causes further organ injury; thrombosis and bleeding may coexist and complicate antithrombotic management.

Treatment-related complications include hemorrhage and perforation during sampling, dysfunction after extensive resections, problems involving reconstructed structures, infections, bone marrow toxicity, and drug- or radiation-related injury. Shrinkage of the mass does not guarantee recovery of a wall already destroyed or a damaged valve. The final assessment of each treatment phase must therefore consider tumor control, cardiovascular function, and quality of life together, promptly identifying conditions that require a new strategy.

References
  1. Tyebally S et al. Cardiac Tumors: JACC CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2020;2(2):293-311.
  2. Basso C et al. Cardiac masses and tumours. Heart. 2016;102(15):1230-1245.
  3. Cresti A et al. Incidence rate of primary cardiac tumors: a 14-year population study. Journal of Cardiovascular Medicine. 2016;17(1):37-43.
  4. Angeli F et al. Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2024;6(6):847-862.
  5. Mousavi N et al. Assessment of Cardiac Masses by Cardiac Magnetic Resonance Imaging: Histological Correlation and Clinical Outcomes. Journal of the American Heart Association. 2019;8(1):e007829.
  6. Shenoy C et al. Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study. European Heart Journal. 2022;43(1):71-80.
  7. Neuville A et al. Intimal sarcoma is the most frequent primary cardiac sarcoma: clinicopathologic and molecular retrospective analysis of 100 primary cardiac sarcomas. The American Journal of Surgical Pathology. 2014;38(4):461-469.
  8. Serrano C et al. SEOM-GEIS Spanish clinical guidelines for the management of soft-tissue sarcomas (2024). Clinical and Translational Oncology. 2025;27(4):1460-1471.
  9. Ramlawi B et al. Surgical Treatment of Primary Cardiac Sarcomas: Review of a Single-Institution Experience. The Annals of Thoracic Surgery. 2016;101(2):698-702.
  10. Zhuang S et al. Primary cardiac lymphoma: a clinicopathological study of 121 cases. Frontiers in Oncology. 2025;14:1509100.
  11. Bussani R et al. Cardiac metastases. Journal of Clinical Pathology. 2007;60(1):27-34.
  12. Lyon AR et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229-4361.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.